nintedanib Capsules 100 mg, 150 mg
Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Comments
MA's Granted
Manufacturer #21467
This global pharmaceutical company is dedicated to improving patients' lives through high-quality, differentiated products and services. They leverage a collaborative network to achieve success in key regions like the EU and North America. Their focus areas include women's health, infectious diseases, and potentially other therapeutic areas based on their recent approvals and launches. They produce prescription medications (including injectables) and tablets, demonstrating expertise in various dosage forms. The company holds GMP certifications and boasts successful product patents, solidifying its commitment to quality and innovation.
Manufacturer usually replies in 23 days
Nintedanib is a medication used to treat idiopathic pulmonary fibrosis as well as in combination therapies for certain types of non-small-cell lung cancer. The nintedanib suppliers and distributors market it as 100mg and 150mg capsules.
The developer and the sole nintedanib manufacturer is Boehringer Ingelheim, who acquired approval to market drug in 2014, under the trade name Ofev (in some countries – Vergatef). Ofev is currently approved in over 70 countries, and due to the ongoing validity of the supplier’s patent, other nintedanib manufacturers have yet to join the market with their formulations.
Costs of nintedanib are relatively high and depend on the concentration of the active ingredient. The retail prices per 60 (100mg) capsules fall into an approximate range of 1,000 EUR to 1,200 EUR, whereas the same amount of 150mg capsules cost around 2,000 EUR to 2,250 EUR.
Pharmaceutical specialists are welcome to browse through offers of nintedanib capsules for sale from nintedanib suppliers and distributors on our pharmaceutical marketplace, or else seek out further useful medical information about the medication online at the official Ofev website.